25E-NBOH is a synthetic psychedelic phenethylamine that carries the character of its parent compound 2C-E -- intense, analytical, cerebral -- into the microgram-potency territory of the N-benzyl series. Structurally, it is 2C-E with an N-(2-hydroxybenzyl) group attached to the terminal nitrogen, a modification that amplifies 5-HT2A receptor binding affinity by roughly an order of magnitude and shifts the active dose range from tens of milligrams down to hundreds of micrograms. The "OH" in NBOH refers to the hydroxyl group on the N-benzyl ring, distinguishing it from the methoxy group found in the more notorious NBOMe series. This is not a trivial chemical footnote -- the NBOH modification produces compounds that retain potent psychedelic activity while appearing to carry somewhat lower acute toxicity risk than their NBOMe counterparts, though "lower" and "low" are not the same thing.
25E-NBOH emerged from the systematic structure-activity work of Martin Hansen and colleagues at the University of Copenhagen, published in 2014. Hansen's group synthesized 48 N-benzylphenethylamine variants and mapped their binding and functional activity at 5-HT2A and 5-HT2C receptors, producing the foundational dataset for the entire NBOH class. The research was oriented toward developing selective pharmacological tools for neuroscience, not recreational drugs. But like most potent psychoactive compounds with published synthesis routes, 25E-NBOH migrated to the research chemical market by the mid-2010s, typically sold on blotter paper and administered sublingually.
The human evidence base for 25E-NBOH is thin. No controlled studies exist. No confirmed fatalities from the compound alone have been documented. What is known comes from structure-activity extrapolation (it should behave broadly like 2C-E but at much lower doses), pharmacological characterization in cell and receptor assays, and the accumulated experience reports of research chemical users in online communities. Those reports describe a psychedelic with moderate visual intensity, a contemplative and introspective headspace, manageable body load relative to NBOMe compounds, and a total duration of 6-8 hours -- a profile that reflects the 2C-E lineage's reputation for cognitive depth over sensory fireworks.
The absence of documented fatalities should not be confused with established safety. 25E-NBOH is active at doses where small measurement errors produce large changes in effect intensity. Its dose-response curve is steep. Vasoconstriction is a pharmacological certainty. Individual sensitivity is unpredictable. And the compound's relative obscurity in drug markets means the sample size of human exposures is far smaller than that of 25I-NBOMe, making any statistical inference about its safety profile unreliable. What can be said is that the NBOH class as a whole appears to be better tolerated than the NBOMe class -- but the NBOMe class set a remarkably low bar.
Safety at a Glance
High Risk- Sublingual Administration Only
- Dose Conservatively and Do Not Redose
- Toxicity: Fatality Data No confirmed human fatalities attributed solely to 25E-NBOH have been documented in the scientific or f...
- Overdose risk: Recognizing a Crisis NBOH compounds have a substantially better acute safety profile than NBOMe c...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 5 hrs – 10 hrsHow It Feels
The come-up is slow, deliberate, and almost polite -- a marked contrast to the aggressive onset of NBOMe compounds. Thirty to forty minutes after placing the blotter under the tongue, the first effects arrive as a subtle brightening of the visual field and a gentle warmth spreading through the torso. There is a mild metallic awareness in the sinuses from the sublingual absorption, but nothing like the harsh chemical burn of NBOMe. The body remains remarkably calm. Heart rate climbs only slightly. Muscles stay relaxed. For anyone who has braced themselves for the punishing body load of the NBOx family, the mildness of 25E-NBOH is almost disorienting.
Over the next hour the visual effects build gradually, reaching a moderate intensity that emphasizes color enhancement and textural depth over dense geometric overlay. Colors become richer and more nuanced -- the world takes on a warm, golden-hour quality regardless of the actual lighting. Surfaces shimmer with subtle iridescence. Textures reveal hidden layers of complexity, wood grain becoming a river delta, concrete becoming a lunar landscape. Patterns that emerge tend toward the organic: flowing curves, gentle spirals, wave-like undulations rather than the hard-edged crystalline fractals of NBOMe. Closed-eye visuals present as slowly shifting fields of warm color, like watching pigment clouds disperse through still water.
The peak arrives around two hours in and sustains for another two to three hours. This is where 2C-E's character asserts itself through the NBOH vehicle. The headspace is lucid, introspective, and distinctly analytical -- thoughts unfold at a measured pace and tend toward the philosophical rather than the emotional. There is a quiet warmth, a sense of being held gently by the experience rather than driven or overwhelmed by it. The cognitive depth exceeds the visual intensity, which is unusual for phenethylamine psychedelics and reflects the 2C-E lineage's reputation as a "thinking person's psychedelic." Music gains emotional resonance and textural richness without the aggressive synesthesia of more potent compounds. The body feels grounded and comfortable, with minimal jaw tension and a pleasant lightness in the limbs.
The descent begins around the five-hour mark and proceeds smoothly. Visuals fade gradually, leaving behind enhanced color perception and a soft shimmer. The mild stimulant component dissipates without jittery residue. Total duration spans six to eight hours -- shorter than LSD, longer than a DMT journey, and paced in a way that feels proportional to what the experience delivers. The afterglow is clean and warm: a lingering appreciation for color and detail, mild emotional openness, and a notable absence of the physical depletion that follows stronger phenethylamines. The overall impression is of a psychedelic that knows what it wants to show you and takes its time getting there, without demanding payment in body load.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(16)
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Frequent urination— Increased urinary frequency beyond normal patterns, caused by diuretic effects or bladder irritation...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(14)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(13)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(3)
- Machinescapes— Machinescapes are complex multisensory hallucinations involving the perception of enormous mechanica...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
25E-NBOH acts as a potent agonist at the serotonin 5-HT2A receptor, the primary molecular target responsible for classical psychedelic effects. The parent compound 2C-E (4-ethyl-2,5-dimethoxyphenethylamine) binds to 5-HT2A with moderate affinity in the micromolar range. The addition of the N-(2-hydroxybenzyl) group extends the molecule into an auxiliary binding pocket within the receptor, increasing affinity to the low nanomolar range -- a roughly 10-15 fold enhancement that mirrors the effect seen across the NBOH series. Functionally, 25E-NBOH activates the canonical Gq-coupled signaling cascade, triggering phospholipase C activation and inositol phosphate accumulation in cortical neurons, the same downstream pathway activated by LSD, psilocybin, and mescaline.
NBOH vs. NBOMe: The Hydroxyl Distinction
The defining structural feature of the NBOH series is the hydroxyl group (-OH) on the 2-position of the N-benzyl ring, replacing the methoxy group (-OCH3) found in NBOMe compounds. This substitution introduces a hydrogen bond donor that interacts differently with specific residues in the 5-HT2A binding pocket. Crystallographic studies of the closely related compound 25CN-NBOH bound to the 5-HT2A receptor (published by Kim et al. in Cell, 2020) have provided atomic-resolution detail of these interactions, showing how the hydroxyl group forms specific contacts with receptor residues that help explain the retained potency of the NBOH series. Whether this structural difference accounts for the apparent (but not definitively established) reduction in peripheral toxicity compared to NBOMe compounds remains an open question.
Selectivity Profile
Like other NBOH compounds, 25E-NBOH shows preferential affinity for 5-HT2A over 5-HT2C, though the precise selectivity ratio has not been characterized as thoroughly as for the benchmark compound of the series, 25CN-NBOH, which exhibits approximately 100-fold 5-HT2A/5-HT2C selectivity. Activity at other receptor targets (dopamine, adrenergic, histamine) is expected to be low based on the selectivity patterns documented across the NBOH class, but specific binding data for 25E-NBOH at these targets are limited.
Route Dependency and Bioavailability
25E-NBOH, like all NBOH and NBOMe compounds, is essentially inactive when swallowed. First-pass hepatic metabolism rapidly destroys the active form before it can reach systemic circulation in sufficient concentration to produce psychoactive effects. Activity is achieved only through sublingual or buccal absorption, with the blotter held against the oral mucosa for 15-20 minutes. This route dependency is pharmacologically important and also serves as a rough identity test: if a blotter must be swallowed to work, it is almost certainly not an NBOH compound.
Pharmacokinetics
No controlled pharmacokinetic data exist for 25E-NBOH in humans. Based on structural analogs and community reports, onset via sublingual administration occurs within 30-60 minutes, with peak effects at 2-3 hours and total duration of 6-8 hours. Hepatic metabolism is presumed to involve CYP450-mediated oxidation, with hydroxylation and O-demethylation as likely primary pathways. The compound is lipophilic and crosses the blood-brain barrier efficiently.
Tolerance
Rapid tolerance develops following a single dose, consistent with all 5-HT2A agonist psychedelics. Full cross-tolerance exists with LSD, psilocybin, mescaline, 2C-B, and other serotonergic psychedelics. Baseline sensitivity returns within approximately 5-7 days.
Detection Methods
Urine Detection
25E-NBOH is not targeted by standard immunoassay-based urine drug screens. However, due to its phenethylamine backbone, there is a theoretical possibility of cross-reactivity with amphetamine immunoassays, though this has not been consistently reported in clinical literature. Specialized LC-MS/MS methods developed for novel psychoactive substances can detect NBOMe compounds and their metabolites in urine for approximately 24 to 48 hours after ingestion, depending on dose and individual metabolism.
Blood and Serum Detection
Blood detection windows for 25E-NBOH are relatively short. Peak plasma concentrations occur within 30 minutes to 2 hours depending on the route of administration (sublingual absorption is typical for NBOMe compounds). Blood concentrations fall below detectable thresholds within 6 to 16 hours for most methods. LC-MS/MS remains the only reliable analytical approach for serum detection, as the doses involved (typically hundreds of micrograms to low milligrams) produce low absolute concentrations.
Standard Drug Panel Inclusion
25E-NBOH is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. It is not specifically targeted by any routine workplace or clinical immunoassay. While some structural similarity to amphetamines exists, cross-reactivity on amphetamine panels is inconsistent and cannot be relied upon for either detection or exclusion. Identification requires specific testing at a reference laboratory equipped for novel psychoactive substance analysis.
Confirmatory Methods
Definitive identification of 25E-NBOH requires LC-MS/MS or high-resolution mass spectrometry (HRMS). GC-MS can also be employed but may require derivatization due to the thermal lability of NBOMe compounds. Reference standards are necessary for quantitative confirmation. Forensic and clinical toxicology laboratories that maintain novel psychoactive substance panels are the only facilities reliably capable of this analysis.
Reagent Testing (Harm Reduction)
Reagent testing is critically important for NBOMe compounds due to their significantly higher toxicity profile compared to classical psychedelics. The Ehrlich reagent shows NO reaction with 25E-NBOH, which is the single most important distinguishing test: any substance sold as a psychedelic that fails to turn purple with Ehrlich may be an NBOMe compound rather than LSD or a tryptamine. The Marquis reagent produces variable results depending on the specific NBOMe compound, ranging from no reaction to green or brown color changes. The Mecke reagent may produce a brown or dark green reaction. For harm reduction purposes, always testing with Ehrlich first is essential. The absence of a purple Ehrlich reaction is a strong warning sign that the substance is not a lysergamide or tryptamine and may be a potentially dangerous NBOMe compound.
Interactions
| Substance | Status | Note |
|---|---|---|
| 2-Aminoindane | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FEA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2,5-DMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1B-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-AL-LAD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-LSD | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 1cP-MiPLA | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Development at the University of Copenhagen (2010-2014)
The NBOH series was developed primarily through the work of Martin Hansen and collaborators at the University of Copenhagen. Hansen's group was investigating structure-activity relationships among N-benzylphenethylamine compounds, seeking to optimize selectivity and potency at the 5-HT2A receptor for use as pharmacological research tools. Their landmark 2014 paper in ACS Chemical Neuroscience reported the synthesis and characterization of 48 N-benzylphenethylamine variants with systematic modifications to both the phenethylamine core and the N-benzyl substituent.
The key finding was that replacing the 2-methoxy group on the N-benzyl ring (the defining feature of Ralf Heim's earlier NBOMe series) with a 2-hydroxyl group yielded compounds -- the NBOH class -- that retained potent 5-HT2A agonism. 25E-NBOH was one of many compounds synthesized as part of this systematic exploration, contributing data points to the broader structure-activity map rather than being developed as an individual target.
25CN-NBOH and the Research Tool Legacy (2014-2017)
The most significant outcome of Hansen's program was the identification of 25CN-NBOH, which exhibited approximately 100-fold selectivity for 5-HT2A over 5-HT2C -- making it one of the most selective 5-HT2A agonists ever characterized. 25CN-NBOH was subsequently adopted widely as a pharmacological research tool, used in PET imaging studies, investigations of receptor signaling bias, and crystallographic work that produced atomic-resolution structures of the 5-HT2A receptor in its active state. 25E-NBOH, while less extensively studied, contributed to the dataset that made this identification possible.
Appearance on Research Chemical Markets (Mid-2010s)
NBOH compounds began appearing on research chemical vendor sites and subsequently in forensic drug seizures by the mid-2010s. They were marketed as alternatives to NBOMe compounds, which were facing increasingly aggressive scheduling worldwide following the deaths attributed to 25I-NBOMe and 25B-NBOMe. NBOH blotters have been identified in forensic analyses in Brazil and Europe. 25E-NBOH specifically occupies a lower-profile position in the market compared to 25B-NBOH and 25C-NBOH, reflecting both the less recreational reputation of the 2C-E scaffold and the more niche demand for analytically demanding psychedelic experiences.
Legal Status
25E-NBOH is not specifically scheduled in most jurisdictions. In the United States, it is not listed under the Controlled Substances Act, but its structural and pharmacological similarity to Schedule I NBOMe compounds means possession or distribution for human consumption could be prosecuted under the Federal Analogue Act of 1986. In the United Kingdom, it is controlled as a Class A substance under the N-benzylphenethylamine catch-all clause. Germany controls it under the NpSG (New Psychoactive Substances Act) since 2016. Legal status varies by country and is subject to change as legislators update analogue and blanket-ban frameworks.
Harm Reduction
Reagent Testing
Use an Ehrlich reagent to rule out indole-containing compounds. LSD turns Ehrlich purple; 25E-NBOH does not. A negative Ehrlich test does not confirm NBOH identity but definitively rules out LSD and psilocybin. For positive identification, Marquis reagent can help distinguish phenethylamine-class compounds. The only way to confirm exact compound identity and dose is mass spectrometry testing through services like DanceSafe, Energy Control, or The Loop.
Sublingual Administration Only
Hold the blotter under the tongue or against the inner cheek for 15-20 minutes. NBOH compounds are destroyed by first-pass metabolism and are inactive when swallowed. Do not drink acidic beverages (citrus juice, soda) immediately before or during absorption, as pH changes may affect mucosal uptake. After 15-20 minutes, spit or swallow the blotter -- the active compound has already been absorbed.
Dose Conservatively and Do Not Redose
The active dose range for 25E-NBOH is incompletely characterized. Community reports suggest 500-1500 µg sublingual, but blotter potency is unverified and individual sensitivity varies. Start with the smallest portion of a blotter you can reasonably cut and wait at least 90 minutes before assessing intensity. The onset is gradual -- effects may still be building well past the point where impatient users decide "it isn't working." Premature redosing is how people accidentally double their dose with compounds that have steep dose-response curves.
The 2C-E scaffold is known for producing unexpectedly intense and demanding experiences at doses that seem moderate by the numbers. 25E-NBOH may inherit this characteristic. Users familiar with the gentler profiles of 25B-NBOH or 25C-NBOH should not assume equivalent intensity at equivalent doses.
Monitor for Vasoconstriction
Vasoconstriction is a pharmacological certainty with all N-benzylphenethylamines, though it appears milder with NBOH compounds than with NBOMe. Check the warmth and color of fingers, toes, and lips periodically during the experience. A well-heated environment reduces peripheral vasoconstriction risk. If extremities become persistently cold, numb, or blue-tinged and do not improve with warming, this is a medical warning sign.
Dangerous Combinations
- Stimulants (amphetamine, cocaine, MDMA) -- compound vasoconstriction and cardiovascular stress; the most dangerous category of combination
- Lithium -- seizure risk with all serotonergic psychedelics; absolutely contraindicated
- MAOIs -- risk of serotonin syndrome; avoid
- Tramadol -- lowers seizure threshold; contraindicated
- Cannabis -- dramatically and unpredictably amplifies intensity, anxiety, and paranoia; the most common escalator of difficult psychedelic experiences
If Things Get Difficult
Benzodiazepines (diazepam 5-10 mg, or lorazepam 1-2 mg) reliably reduce psychedelic intensity and are the appropriate intervention for acute panic or overwhelming effects. Change the environment: different room, different music, step outside. A calm, sober companion providing reassurance that the experience is temporary and that you are physically safe is the single most effective harm reduction measure during a difficult experience. Call emergency services if vasoconstriction becomes severe, chest pain develops, seizures occur, or consciousness is lost.
Toxicity & Safety
Fatality Data
No confirmed human fatalities attributed solely to 25E-NBOH have been documented in the scientific or forensic literature. This is a meaningful data point but not a safety endorsement. The absence of fatalities reflects the convergence of two factors: the NBOH class appears to be better tolerated pharmacologically than the NBOMe class, and NBOH compounds have far lower market prevalence, meaning the total number of human exposures is much smaller. A substance can be dangerous without having killed anyone yet, particularly when the sample size is small.
Vasoconstriction
Peripheral vasoconstriction is a pharmacological certainty with all N-benzylphenethylamine psychedelics, including NBOH compounds. It manifests as cold, pale, or numb extremities (fingers, toes, lips), tightness in the chest, and elevated blood pressure. Community reports suggest the vasoconstriction from NBOH compounds is milder than from NBOMe compounds, but "milder" is relative and individual variation is significant. Risk is substantially elevated by concurrent use of stimulants, nicotine, or other vasoconstrictors, and in individuals with pre-existing cardiovascular conditions, hypertension, or Raynaud's phenomenon.
Cardiovascular Effects
Tachycardia and blood pressure elevation are expected effects based on 5-HT2A agonism and possible adrenergic receptor activity. These are generally tolerable in healthy adults at moderate doses but represent real risk in individuals with cardiac conditions and dangerous synergy with stimulant drugs.
Seizure Risk
Seizures have been documented with NBOMe compounds at high doses and are a plausible risk with NBOH compounds given the shared receptor pharmacology, particularly at high doses, in combination with seizure-threshold-lowering drugs (tramadol, lithium), or in individuals with pre-existing seizure disorders. No seizures specifically attributed to 25E-NBOH have been published, but this absence may reflect limited reporting rather than pharmacological impossibility.
Psychological Risks
The 2C-E scaffold is known for producing psychologically intense and demanding experiences that can be disproportionate to the apparent "level" of visual or physical effects. 25E-NBOH may carry this characteristic. Acute anxiety, panic, thought loops, paranoia, and difficult introspective content are plausible adverse effects, particularly at higher doses, in unfavorable settings, or in individuals with vulnerability to anxiety or psychotic disorders.
Drug Interactions
- Stimulants and vasoconstrictors -- contraindicated; compounding vasoconstriction and cardiovascular load
- Lithium -- absolutely contraindicated; seizure risk with all serotonergic psychedelics
- MAOIs -- risk of serotonin syndrome; avoid
- Tramadol -- lowers seizure threshold; contraindicated
- Cannabis -- unpredictable intensity amplification and increased psychological adverse event risk
Contraindications
Cardiovascular disease, hypertension, vascular disorders (including Raynaud's), personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder, bipolar I), seizure disorders, and concurrent use of lithium, MAOIs, stimulants, or tramadol.
Addiction Potential
25E-NBOH is not addictive. It produces no physical dependence, no withdrawal syndrome, and carries no pharmacological basis for compulsive redosing. Serotonergic psychedelics as a class rank at the bottom of every major addiction liability assessment, and 25E-NBOH fits this pattern completely. Rapid tolerance develops within 24-48 hours of a single dose, making daily use self-defeating as each successive day produces diminished effects. Full cross-tolerance exists with LSD, psilocybin, mescaline, 2C-B, and all other 5-HT2A-mediated psychedelics. Baseline sensitivity returns within approximately 5-7 days. The introspective and occasionally demanding character of the 2C-E-derived headspace further discourages casual or compulsive use patterns -- this is not a substance most people are eager to take again immediately. A small minority of psychedelic users develop psychological reliance on repeated psychedelic experiences as a coping mechanism or identity framework, but this pattern is not pharmacologically driven and is not specific to any individual compound.
Overdose Information
Recognizing a Crisis
NBOH compounds have a substantially better acute safety profile than NBOMe compounds, but overdose remains possible, particularly at high doses, with combinations, or in vulnerable individuals. The line between "overwhelming psychedelic experience" and "medical emergency" is defined by the presence of physiological danger signs.
Seek Immediate Medical Attention For
- Seizures or uncontrollable muscle jerking
- Severe vasoconstriction: extremities that are cold, blue, numb, and not responding to warming
- Chest pain or difficulty breathing
- Body temperature that feels dangerously elevated
- Loss of consciousness or complete unresponsiveness
- Extreme agitation with inability to communicate or recognize surroundings
Psychological Overdose
More likely than physiological crisis is overwhelming psychological intensity. The 2C-E lineage is known for producing experiences that become unmanageably intense in a way that is more cognitive and emotional than visual -- thought loops that feel inescapable, anxiety spirals, a sense that something is fundamentally wrong that cannot be articulated. These experiences are genuinely distressing but are not life-threatening on their own.
For psychological crisis: change the environment, provide calm physical presence, offer simple reassurance ("You took a substance, this is temporary, you are safe"). Benzodiazepines (diazepam 5-10 mg, lorazepam 1-2 mg) reliably reduce intensity and are the appropriate pharmacological intervention.
Hospital Management
There is no specific antidote for NBOH toxicity. Treatment is supportive:
- Seizures: Benzodiazepines first-line
- Vasoconstriction: Warming, IV fluids, monitoring; vasodilators if severe
- Cardiovascular: IV fluids, monitoring, short-acting antihypertensives if blood pressure is dangerously elevated
- Agitation: Benzodiazepines preferred over antipsychotics
- Hyperthermia: Active external cooling if present
Prevention
The most effective overdose prevention measures are conservative initial dosing, never redosing during the onset period, avoiding all dangerous combinations (stimulants, lithium, MAOIs, tramadol), and having a sober companion present who knows what was taken and can call for help if needed. Good Samaritan laws protect people who call emergency services during drug-related medical events in most jurisdictions.
Tolerance
| Full | Develops almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
United States: 25E-NBOH is not regulated under the Controlled Substances Act of 1970, however it's structurally similar to substances from the NBOMe class. Meaning that 25E-NBOH falls under the the Federal Analogue Act of 1986. This considers it as s Schedule I controlled substance, making illegal to manufacture, buy, possess, process, or distribute without a license from the Drug Enforcement Administration (DEA).
Responsible use
Psychedelic
Phenethylamines
25E-NBOH (Wikipedia)
25E-NBOH (Isomer Design)
Experience Reports (1)
Tips (5)
If you experience anxiety or thought loops on 25E-NBOH, change your physical environment: move to a different room, go outside, change the music, or hold something cold. A change of scenery can instantly shift a difficult headspace.
Use a milligram scale to weigh 25E-NBOH if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 25E-NBOH and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Keep a benzodiazepine like alprazolam on hand as an emergency trip abort tool when using 25E-NBOH. Even just knowing you have one available provides psychological reassurance. It will not fully end the trip but significantly reduces intensity.
Set and setting are paramount with 25E-NBOH. Choose a familiar, comfortable environment where you feel safe. Have trusted company or a trip sitter, especially for your first experience. Avoid stressful locations or social obligations.
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 25E-NBOH - TripSit Factsheet
TripSit factsheet for 25E-NBOH
tripsit - 25E-NBOH - Wikipedia
Wikipedia article on 25E-NBOH
wikipedia